Literature DB >> 12676880

The site-specific transport and metabolism of tacrolimus in rat small intestine.

Shigeki Tamura1, Yuji Tokunaga, Rinta Ibuki, Gordon L Amidon, Hitoshi Sezaki, Shinji Yamashita.   

Abstract

The objective of this study was to evaluate the absorption of tacrolimus by means of simultaneous perfusion of intestinal lumen and blood vessels in rats. In our previous report, the permeability of tacrolimus was found to be higher in the jejunum than in the ileum or colon, suggesting the site-dependent absorption after oral administration. However, in this article, simultaneous perfusion technique revealed that the extent of absorption into blood vessels was similar in the jejunum and the ileum regardless of the site difference in permeability as the absorption rate. In addition to the multidrug resistance-associated protein-mediated efflux, cytochrome P450 (P450)-mediated metabolism could be a possible mechanism to explain the inconsistencies in the site dependence of tacrolimus absorption. Two enzyme inhibitors, ketoconazole and midazolam, were coperfused in rat intestinal lumen with tacrolimus to specify the effect of P-gp and P450. In the jejunum, both inhibitors significantly enhanced the absorbed amount of tacrolimus, whereas the permeability was not affected. It was suggested that both inhibitors mainly suppress P450-mediated metabolism in the upper region of the intestine. In contrast, in the ileum, ketoconazole significantly enhanced both the absorbed amount and the permeability of tacrolimus. However, midazolam failed to enhance the absorption of tacrolimus, indicating the dominant role of P-glycoprotein (P-gp)-mediated efflux in the lower region. From these findings, it is concluded that the site-dependent differences in P-gp and/or P450 activity could be the prime cause of large intra- and interindividual variability in the oral absorption of tacrolimus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12676880     DOI: 10.1124/jpet.103.050716

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Novel gastroretentive sustained-release tablet of tacrolimus based on self-microemulsifying mixture: in vitro evaluation and in vivo bioavailability test.

Authors:  Yan-ping Wang; Yong Gan; Xin-xin Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-09-19       Impact factor: 6.150

2.  Excess fluid distribution affects tacrolimus absorption in peritoneal dialysis patients.

Authors:  Tadashi Sofue; Masashi Inui; Hideyasu Kiyomoto; Kumiko Moriwaki; Taiga Hara; Kazunori Yamaguchi; Noriyasu Fukuoka; Kazuko Banno; Akira Nishiyama; Yoshiyuki Kakehi; Masakazu Kohno
Journal:  Clin Exp Nephrol       Date:  2012-12-27       Impact factor: 2.801

3.  Extended tacrolimus release via the combination of lipid-based solid dispersion and HPMC hydrogel matrix tablets.

Authors:  Hui Xu; Li Liu; Xuehui Li; Junyuan Ma; Rui Liu; Shaoning Wang
Journal:  Asian J Pharm Sci       Date:  2018-09-08       Impact factor: 6.598

4.  Investigation of the Impact of CYP3A5 Polymorphism on Drug-Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling.

Authors:  Qingfeng He; Fengjiao Bu; Hongyan Zhang; Qizhen Wang; Zhijia Tang; Jing Yuan; Hai-Shu Lin; Xiaoqiang Xiang
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-27

5.  Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation.

Authors:  Pere Fontova; Helena Colom; Raül Rigo-Bonnin; Lisanne N van Merendonk; Anna Vidal-Alabró; Nuria Montero; Edoardo Melilli; Maria Meneghini; Anna Manonelles; Josep M Cruzado; Juan Torras; Josep Maria Grinyó; Oriol Bestard; Nuria Lloberas
Journal:  Front Pharmacol       Date:  2021-03-17       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.